A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
1/2期
提前终止
NCT05949632
| 适应症 | Advanced Solid Tumors |
|---|
| 分期 | 1/2期 |
|---|
| 申办方 | Incyte Corporation |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 5 人 |
|---|
| 干预（药物） | INCB099280, axitinib |
|---|
| 开始日期 | 2024年4月16日 |
|---|
| 完成日期 | 2025年6月6日 |
|---|
| 结果公布日 | 2026年6月4日 |
|---|
摘要
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
up to 3 weeks · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 1 Participants |
|---|
Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
up to approximately 1 year · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 5 Participants |
|---|
Part 1: Number of Participants With TEAEs Leading to a Dosing Modification (Treatment Interruption, Dose Reduction, and Permanent Discontinuation of Either Study Drug)
up to approximately 1 year · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 5 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 0 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 4 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 3 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 1 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。